Addressing Pluvicto supply issues: Czernin and Calais comment on potential solutions to insufficient supply and slowed access to ^{177}Lu-PSMA-617 and preview a related editorial in this issue of *JNM*. . . . . ***Page 343***

Discussions with leaders: Ramsey Badawi talks with Hélène Langevin, director of the National Center for Complementary and Integrative Health, about her career-long perspective on medical treatment for the "whole patient." . . . . . ***Page 344***

"Last mile" for radioligand therapy: Pomykala and colleagues look at elements required to translate newly approved nuclear theranostics into routine clinical use, including the challenges of supply chain and distribution logistics. . . . . ***Page 347***

^{177}Lu-PSMA in prostate cancer: Ravi and colleagues describe the process of clinical implementation of ^{177}Lu-PSMA-617 at a major academic center, highlighting successes and hurdles, including referrals, supply issues, and patient selection. . . . . ***Page 349***

ER-targeted ^{18}F-FES PET AUC: Ulaner and colleagues from an SNMMI-convened expert work group provide a brief summary of recently published appropriate use criteria for ^{18}F-FES PET detection of estrogen receptor–positive breast cancer, including clinical scenarios. . . . . ***Page 351***

PET/CT or CE-CT in breast cancer: Vogsen and colleagues compare contrast-enhanced CT and ^{18}F-FDG PET/CT for response monitoring in metastatic breast cancer using standardized response evaluation criteria, focusing on early detection of progressive disease. . . . . ***Page 355***

PET/CT negative predictive value: Subramaniam and colleagues report on the negative predictive value of a 12- to 14-wk posttreatment PET/CT for 2-y progression-free survival and locoregional control in patients with p16-positive locoregionally advanced oropharyngeal cancer. . . ***Page 362***

^{68}Ga-FAPI PET and COVID-19 pitfalls: Demmert and colleagues assess ^{18}F-FDG and ^{68}Ga-FAPI-46 PET/CT tumor staging in a series of patients after COVID vaccination and discuss the potential of FAPI to avoid confounding postvaccination findings and provide superior tumor localization. . . . . ***Page 368***

PSMA targeting in salivary gland tumors: Civan and colleagues analyze the diagnostic performance of PSMA PET/CT and the dosimetry, efficacy, and safety of ^{177}Lu-PSMA-617 radioligand therapy in salivary gland malignancies. . . . . ***Page 372***

PSMA vs. GRP-R PET/CT in prostate cancer: Schollhammer and colleagues describe a prospective head-to-head comparison of PSMA- and gastrin-releasing peptide receptor–targeted imaging at initial prostate cancer staging to understand how these can be used or combined in clinical practice. . . . . ***Page 379***

^{68}Ga-FAP-2286 in various cancers: Pang and colleagues assess the diagnostic accuracy of ^{68}Ga-FAP-2286, compared with ^{18}F-FDG and ^{68}Ga-FAPI-46, to detect primary and metastatic lesions in patients with various types of cancer. . . ***Page 386***

Predicting IBLs on PSMA PET/CT: Phelps and colleagues define variables that predict whether indeterminate bone lesions in patients with high-risk primary or biochemically recurrent prostate cancer are likely malignant or benign using features on ^{18}F-DCFPyL PET/CT. . . . . ***Page 395***

^{177}Lu-PSMA-I&T for mCRPC: Karimzadeh and colleagues detail prostate-specific antigen response and progression-free and overall survival in patients with metastatic castration-resistant prostate cancer treated with ^{177}Lu-PSMA-I&T and identify clinical and imaging prognostic factors. . . . . ***Page 402***

SPECT and ^{177}Lu-PSMA response: John and colleagues evaluate changes in ^{177}Lu-PSMA SPECT/CT quantitative parameters to monitor ^{177}Lu-PSMA treatment response in men with progressive metastatic castration-resistant prostate cancer. . . . . ***Page 410***

Vessel wall total-body PET: Derlin and colleagues use ultrasensitive, extended-field-of-view total-body PET to explore biologic hallmarks of previously difficult-to-evaluate low-signal cardiac vessel wall pathology and crosstalk with other organs. . . . . ***Page 416***

PET and neutrophil elastase: Puuvuori and colleagues assess the novel neutrophil elastase inhibitor ^{11}C-GW457427 in a pig model of acute respiratory distress syndrome, for PET detection and quantification of neutrophil activity in the lungs. . . . . ***Page 423***

^{68}Ga-DOTA CSF PET: Evangelou and colleagues evaluate ^{68}Ga-DOTA PET imaging of the cerebrospinal fluid space as a state-of-the-art approach to radionuclide cisternography in patients with suspected intracranial hypotension resulting from spinal CSF leaks. . . . . ***Page 430***

Plasma pTau181 vs. tau PET: Coomans and colleagues compare plasma tau phosphorylated at threonine-181 PET and tau PET in participants along the Alzheimer disease continuum, including evaluation of staging and progression. . . ***Page 437***

Visual interpretation of ^{18}F-MK-6240: Seibyl and colleagues describe development of a visual assessment method for ^{18}F-MK-6240 PET that provides both an overall assessment of brain tauopathy and regional characterization of abnormal tau deposition. . . . . ***Page 444***

Age and off-target retention of [^{18}F]MK6240: Tissot and colleagues look at common reference region estimates in the cerebellum over time and evaluate the effects of age-related and off-target retention on longitudinal PET quantification of [^{18}F]MK6240 in target regions. . . . . ***Page 452***

Tau PET tracers in CTE: Varlow and Vasdev conduct a head-to-head in vitro evaluation of 5 tau PET radiotracers in subjects pathologically diagnosed with chronic traumatic encephalopathy. . . . . ***Page 460***

MDMA and neurovascular uncoupling: Ionescu and colleagues delineate the acute effects of 3,4-methylenedioxymethamphetamine using simultaneous PET/fMRI in rats, with a goal of identifying more robust measures for pharmacologic research. . . . . ***Page 466***

AI-based SPECT attenuation correction: Shanbhag and colleagues develop and validate a deep-learning model to generate simulated attenuation correction myocardial perfusion images directly from non-corrected SPECT, without the need for CT. . . . . ***Page 472***

Lensless radiomicroscope: Klein and colleagues describe development of the lensless radiomicroscope, a new imaging modality, for in vitro cellular-resolution imaging of β- and α-emitting radionuclides. . . . . ***Page 479***

Adverse events after extravasation: Parihar and colleagues study the occurrence of short- and long-term clinical adverse events in patients after ^{99m}Tc-methylene diphosphonate whole-body bone scintigraphy with reported radiopharmaceutical extravasation. . . . . ***Page 485***

Perspective on diagnostic RPE: van der Pol and Mottaghy comment on radiopharmaceutical extravasation and a related article in this issue of *JNM*. . . . . ***Page 491***

Multiregion mouse kidney model: Vargas and colleagues describe development of a multiregion model of a mouse kidney based on high-resolution MRI data, with utility in calculating reference dose factors for specific mouse kidney tissues. . . . . ***Page 493***

Progression or response: Parihar and colleagues offer a case study in a patient with responding Hodgkin lymphoma and new liver lesions on ^{18}F-FDG PET/CT. . . . . ***Page 500***